$89.02
1.09% today
Nasdaq, Oct 23, 09:44 pm CET
ISIN
US45337C1027
Symbol
INCY

Incyte Stock price

$88.06
+3.33 3.93% 1M
+30.68 53.47% 6M
+18.99 27.49% YTD
+22.47 34.26% 1Y
+15.59 21.51% 3Y
-2.43 2.69% 5Y
-20.96 19.23% 10Y
+83.12 1,682.59% 20Y
Nasdaq, Closing price Wed, Oct 22 2025
+0.76 0.87%
ISIN
US45337C1027
Symbol
INCY
Industry

Key metrics

Basic
Market capitalization
$17.2b
Enterprise Value
$14.8b
Net debt
positive
Cash
$2.4b
Shares outstanding
194.1m
Valuation (TTM | estimate)
P/E
20.1 | 14.0
P/S
3.8 | 3.5
EV/Sales
3.2 | 3.0
EV/FCF
15.5
P/B
4.1
Financial Health
Equity Ratio
63.3%
Return on Equity
1.0%
ROCE
21.9%
ROIC
63.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.6b | $4.9b
EBITDA
$1.0b | $1.7b
EBIT
$994.5m | $1.5b
Net Income
$870.9m | $1.2b
Free Cash Flow
$958.1m
Growth (TTM | estimate)
Revenue
18.9% | 16.4%
EBITDA
1,057.5% | 1,164.4%
EBIT
1,425.1% | 1,260.6%
Net Income
794.8% | 3,654.8%
Free Cash Flow
793.6%
Margin (TTM | estimate)
Gross
93.4%
EBITDA
22.2% | 34.6%
EBIT
21.7%
Net
19.0% | 24.8%
Free Cash Flow
20.9%
More
EPS
$4.4
FCF per Share
$4.9
Short interest
6.2%
Employees
3k
Rev per Employee
$1.6m
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,021 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Incyte forecast:

16x Buy
48%
16x Hold
48%
1x Sell
3%

Analyst Opinions

33 Analysts have issued a Incyte forecast:

Buy
48%
Hold
48%
Sell
3%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,585 4,585
19% 19%
100%
- Direct Costs 302 302
24% 24%
7%
4,283 4,283
19% 19%
93%
- Selling and Administrative Expenses 1,293 1,293
13% 13%
28%
- Research and Development Expense 1,971 1,971
17% 17%
43%
1,019 1,019
1,058% 1,058%
22%
- Depreciation and Amortization 24 24
6% 6%
1%
EBIT (Operating Income) EBIT 995 995
1,425% 1,425%
22%
Net Profit 871 871
795% 795%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Positive
Seeking Alpha
one day ago
Incyte Corporation offers strong growth potential and a low valuation, driven by expanding margins and a robust earnings outlook. INCY's revenue is anchored by Jakafi, but a diverse pipeline and potential acquisitions could offset future patent expirations. Growth is expected from products like Monjuvi, Opzelura, Niktimvo, and pipeline compounds such as 989 and povorcitinib.
Neutral
Seeking Alpha
3 days ago
Incyte Corporation (NASDAQ:INCY ) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer October 19, 2025 1:30 PM EDT Company Participants Pablo Cagnoni - President and Head of Research & Development Patrick Mayes - Vice President of Biotherapeutic Research Ekaterine Asatiani Steven Stein - Executive VP & Chief Medical Officer Co...
Neutral
Business Wire
4 days ago
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO25--Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced PDAC.
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,617
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today